Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

News Conference News TCT 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

Todd Neale

October 31, 2024

Presentation TCT 2024

TCT 102: First-in-Man Experience With the Self-Expandable A-Flux Coronary Sinus Reducer for Treating Symptomatic Ischemic Heart Disease

Presenter: Francesco Giannini

October 30, 2024

Presentation TCT 2024

The Transformation of Diagnosis and Risk Profiling for Ischemic Heart disease: An AI Case Study

Presenter: James Min

October 30, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

Presentation TCT 2024

TCT 250: Temporal Trends in Ischemic Heart Disease-related Mortality in Canada Over the Past 3 Decades

Presenter: Ahmed Abdulelah

October 29, 2024

Presentation TCT 2024

Final Results of the Novel Healing-Targeted DES With Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation After DES Implantation in Coronary Artery Disease: 5-Year Results of the PIONEER III Trial

Presenter: Thomas Sharp

October 28, 2024

Advertisement

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

TCT 102: First-in-Man Experience With the Self-Expandable A-Flux Coronary Sinus Reducer for Treating Symptomatic Ischemic Heart Disease

The Transformation of Diagnosis and Risk Profiling for Ischemic Heart disease: An AI Case Study

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

TCT 250: Temporal Trends in Ischemic Heart Disease-related Mortality in Canada Over the Past 3 Decades

Final Results of the Novel Healing-Targeted DES With Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation After DES Implantation in Coronary Artery Disease: 5-Year Results of the PIONEER III Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content